Tesamorelin
Explore peptide research and guides on tesamorelin.
Tesamorelin
Tesamorelin and HIV Lipodystrophy
Tesamorelin reduced visceral fat by 15-20% in HIV patients with lipodystrophy. Here is the clinical evidence behind the only FDA-approved GHRH analog.
TesamorelinTesamorelin and Liver Fat: MASH Research
Tesamorelin reduced liver fat by 37% and halved fibrosis progression in HIV-associated NAFLD trials. What this GHRH analog means for broader MASH treatment.
TesamorelinTesamorelin (Egrifta): The FDA-Approved GHRH Analog
Tesamorelin is the only FDA-approved GHRH analog for HIV lipodystrophy. Clinical trial data on visceral fat, liver fat, cognition, and emerging research.
TesamorelinTesamorelin's Cognitive Effects: An Unexpected Finding
A 20-week RCT found tesamorelin improved executive function in MCI and healthy older adults while raising brain GABA levels. Here is the cognitive evidence.